The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Allogeneic Universal Cell Therapy Market Research Report 2024

Global Allogeneic Universal Cell Therapy Market Research Report 2024

Publishing Date : Jan, 2024

License Type :
 

Report Code : 1893841

No of Pages : 101

Ask Your Query
Synopsis
Allogeneic universal cells, also called off-the-shelf cells, refer to a type of cell therapy that uses cells from different individuals instead of the patient's own cells for treatment.
The global Allogeneic Universal Cell Therapy market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Allogeneic Universal Cell Therapy is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Allogeneic Universal Cell Therapy is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Allogeneic Universal Cell Therapy in Hematoma is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Allogeneic Universal Cell Therapy include Novartis, Gilead Sciences, Yi Zun Biology, Bangyao Biotechnology, Usano, Cellectis, Allogene, Caribou and Poseida Therapeutics, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Allogeneic Universal Cell Therapy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Allogeneic Universal Cell Therapy.
Report Scope
The Allogeneic Universal Cell Therapy market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Allogeneic Universal Cell Therapy market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Allogeneic Universal Cell Therapy companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Novartis
Gilead Sciences
Yi Zun Biology
Bangyao Biotechnology
Usano
Cellectis
Allogene
Caribou
Poseida Therapeutics
Keji Pharmaceutical
Beiheng Biotechnology
Grace Biotechnology
Nkarta Therapeutic
Fate Therapeutics
Ruishun Biology
Cynata
Fate
Century
Cytovia
BeiGene
Cell-Origin
Neukio
Segment by Type
CAR-T cell therapy
Natural Universal Cell Therapy
Immune Cell Therapy
Segment by Application
Hematoma
Solid Tumor
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Allogeneic Universal Cell Therapy companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Allogeneic Universal Cell Therapy Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 CAR-T cell therapy
1.2.3 Natural Universal Cell Therapy
1.2.4 Immune Cell Therapy
1.3 Market by Application
1.3.1 Global Allogeneic Universal Cell Therapy Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hematoma
1.3.3 Solid Tumor
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Allogeneic Universal Cell Therapy Market Perspective (2019-2030)
2.2 Allogeneic Universal Cell Therapy Growth Trends by Region
2.2.1 Global Allogeneic Universal Cell Therapy Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Allogeneic Universal Cell Therapy Historic Market Size by Region (2019-2024)
2.2.3 Allogeneic Universal Cell Therapy Forecasted Market Size by Region (2025-2030)
2.3 Allogeneic Universal Cell Therapy Market Dynamics
2.3.1 Allogeneic Universal Cell Therapy Industry Trends
2.3.2 Allogeneic Universal Cell Therapy Market Drivers
2.3.3 Allogeneic Universal Cell Therapy Market Challenges
2.3.4 Allogeneic Universal Cell Therapy Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Allogeneic Universal Cell Therapy Players by Revenue
3.1.1 Global Top Allogeneic Universal Cell Therapy Players by Revenue (2019-2024)
3.1.2 Global Allogeneic Universal Cell Therapy Revenue Market Share by Players (2019-2024)
3.2 Global Allogeneic Universal Cell Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Allogeneic Universal Cell Therapy Revenue
3.4 Global Allogeneic Universal Cell Therapy Market Concentration Ratio
3.4.1 Global Allogeneic Universal Cell Therapy Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Allogeneic Universal Cell Therapy Revenue in 2023
3.5 Allogeneic Universal Cell Therapy Key Players Head office and Area Served
3.6 Key Players Allogeneic Universal Cell Therapy Product Solution and Service
3.7 Date of Enter into Allogeneic Universal Cell Therapy Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Allogeneic Universal Cell Therapy Breakdown Data by Type
4.1 Global Allogeneic Universal Cell Therapy Historic Market Size by Type (2019-2024)
4.2 Global Allogeneic Universal Cell Therapy Forecasted Market Size by Type (2025-2030)
5 Allogeneic Universal Cell Therapy Breakdown Data by Application
5.1 Global Allogeneic Universal Cell Therapy Historic Market Size by Application (2019-2024)
5.2 Global Allogeneic Universal Cell Therapy Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Allogeneic Universal Cell Therapy Market Size (2019-2030)
6.2 North America Allogeneic Universal Cell Therapy Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Allogeneic Universal Cell Therapy Market Size by Country (2019-2024)
6.4 North America Allogeneic Universal Cell Therapy Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Allogeneic Universal Cell Therapy Market Size (2019-2030)
7.2 Europe Allogeneic Universal Cell Therapy Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Allogeneic Universal Cell Therapy Market Size by Country (2019-2024)
7.4 Europe Allogeneic Universal Cell Therapy Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Allogeneic Universal Cell Therapy Market Size (2019-2030)
8.2 Asia-Pacific Allogeneic Universal Cell Therapy Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Allogeneic Universal Cell Therapy Market Size by Region (2019-2024)
8.4 Asia-Pacific Allogeneic Universal Cell Therapy Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Allogeneic Universal Cell Therapy Market Size (2019-2030)
9.2 Latin America Allogeneic Universal Cell Therapy Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Allogeneic Universal Cell Therapy Market Size by Country (2019-2024)
9.4 Latin America Allogeneic Universal Cell Therapy Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Allogeneic Universal Cell Therapy Market Size (2019-2030)
10.2 Middle East & Africa Allogeneic Universal Cell Therapy Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Allogeneic Universal Cell Therapy Market Size by Country (2019-2024)
10.4 Middle East & Africa Allogeneic Universal Cell Therapy Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Novartis
11.1.1 Novartis Company Detail
11.1.2 Novartis Business Overview
11.1.3 Novartis Allogeneic Universal Cell Therapy Introduction
11.1.4 Novartis Revenue in Allogeneic Universal Cell Therapy Business (2019-2024)
11.1.5 Novartis Recent Development
11.2 Gilead Sciences
11.2.1 Gilead Sciences Company Detail
11.2.2 Gilead Sciences Business Overview
11.2.3 Gilead Sciences Allogeneic Universal Cell Therapy Introduction
11.2.4 Gilead Sciences Revenue in Allogeneic Universal Cell Therapy Business (2019-2024)
11.2.5 Gilead Sciences Recent Development
11.3 Yi Zun Biology
11.3.1 Yi Zun Biology Company Detail
11.3.2 Yi Zun Biology Business Overview
11.3.3 Yi Zun Biology Allogeneic Universal Cell Therapy Introduction
11.3.4 Yi Zun Biology Revenue in Allogeneic Universal Cell Therapy Business (2019-2024)
11.3.5 Yi Zun Biology Recent Development
11.4 Bangyao Biotechnology
11.4.1 Bangyao Biotechnology Company Detail
11.4.2 Bangyao Biotechnology Business Overview
11.4.3 Bangyao Biotechnology Allogeneic Universal Cell Therapy Introduction
11.4.4 Bangyao Biotechnology Revenue in Allogeneic Universal Cell Therapy Business (2019-2024)
11.4.5 Bangyao Biotechnology Recent Development
11.5 Usano
11.5.1 Usano Company Detail
11.5.2 Usano Business Overview
11.5.3 Usano Allogeneic Universal Cell Therapy Introduction
11.5.4 Usano Revenue in Allogeneic Universal Cell Therapy Business (2019-2024)
11.5.5 Usano Recent Development
11.6 Cellectis
11.6.1 Cellectis Company Detail
11.6.2 Cellectis Business Overview
11.6.3 Cellectis Allogeneic Universal Cell Therapy Introduction
11.6.4 Cellectis Revenue in Allogeneic Universal Cell Therapy Business (2019-2024)
11.6.5 Cellectis Recent Development
11.7 Allogene
11.7.1 Allogene Company Detail
11.7.2 Allogene Business Overview
11.7.3 Allogene Allogeneic Universal Cell Therapy Introduction
11.7.4 Allogene Revenue in Allogeneic Universal Cell Therapy Business (2019-2024)
11.7.5 Allogene Recent Development
11.8 Caribou
11.8.1 Caribou Company Detail
11.8.2 Caribou Business Overview
11.8.3 Caribou Allogeneic Universal Cell Therapy Introduction
11.8.4 Caribou Revenue in Allogeneic Universal Cell Therapy Business (2019-2024)
11.8.5 Caribou Recent Development
11.9 Poseida Therapeutics
11.9.1 Poseida Therapeutics Company Detail
11.9.2 Poseida Therapeutics Business Overview
11.9.3 Poseida Therapeutics Allogeneic Universal Cell Therapy Introduction
11.9.4 Poseida Therapeutics Revenue in Allogeneic Universal Cell Therapy Business (2019-2024)
11.9.5 Poseida Therapeutics Recent Development
11.10 Keji Pharmaceutical
11.10.1 Keji Pharmaceutical Company Detail
11.10.2 Keji Pharmaceutical Business Overview
11.10.3 Keji Pharmaceutical Allogeneic Universal Cell Therapy Introduction
11.10.4 Keji Pharmaceutical Revenue in Allogeneic Universal Cell Therapy Business (2019-2024)
11.10.5 Keji Pharmaceutical Recent Development
11.11 Beiheng Biotechnology
11.11.1 Beiheng Biotechnology Company Detail
11.11.2 Beiheng Biotechnology Business Overview
11.11.3 Beiheng Biotechnology Allogeneic Universal Cell Therapy Introduction
11.11.4 Beiheng Biotechnology Revenue in Allogeneic Universal Cell Therapy Business (2019-2024)
11.11.5 Beiheng Biotechnology Recent Development
11.12 Grace Biotechnology
11.12.1 Grace Biotechnology Company Detail
11.12.2 Grace Biotechnology Business Overview
11.12.3 Grace Biotechnology Allogeneic Universal Cell Therapy Introduction
11.12.4 Grace Biotechnology Revenue in Allogeneic Universal Cell Therapy Business (2019-2024)
11.12.5 Grace Biotechnology Recent Development
11.13 Nkarta Therapeutic
11.13.1 Nkarta Therapeutic Company Detail
11.13.2 Nkarta Therapeutic Business Overview
11.13.3 Nkarta Therapeutic Allogeneic Universal Cell Therapy Introduction
11.13.4 Nkarta Therapeutic Revenue in Allogeneic Universal Cell Therapy Business (2019-2024)
11.13.5 Nkarta Therapeutic Recent Development
11.14 Fate Therapeutics
11.14.1 Fate Therapeutics Company Detail
11.14.2 Fate Therapeutics Business Overview
11.14.3 Fate Therapeutics Allogeneic Universal Cell Therapy Introduction
11.14.4 Fate Therapeutics Revenue in Allogeneic Universal Cell Therapy Business (2019-2024)
11.14.5 Fate Therapeutics Recent Development
11.15 Ruishun Biology
11.15.1 Ruishun Biology Company Detail
11.15.2 Ruishun Biology Business Overview
11.15.3 Ruishun Biology Allogeneic Universal Cell Therapy Introduction
11.15.4 Ruishun Biology Revenue in Allogeneic Universal Cell Therapy Business (2019-2024)
11.15.5 Ruishun Biology Recent Development
11.16 Cynata
11.16.1 Cynata Company Detail
11.16.2 Cynata Business Overview
11.16.3 Cynata Allogeneic Universal Cell Therapy Introduction
11.16.4 Cynata Revenue in Allogeneic Universal Cell Therapy Business (2019-2024)
11.16.5 Cynata Recent Development
11.17 Fate
11.17.1 Fate Company Detail
11.17.2 Fate Business Overview
11.17.3 Fate Allogeneic Universal Cell Therapy Introduction
11.17.4 Fate Revenue in Allogeneic Universal Cell Therapy Business (2019-2024)
11.17.5 Fate Recent Development
11.18 Century
11.18.1 Century Company Detail
11.18.2 Century Business Overview
11.18.3 Century Allogeneic Universal Cell Therapy Introduction
11.18.4 Century Revenue in Allogeneic Universal Cell Therapy Business (2019-2024)
11.18.5 Century Recent Development
11.19 Cytovia
11.19.1 Cytovia Company Detail
11.19.2 Cytovia Business Overview
11.19.3 Cytovia Allogeneic Universal Cell Therapy Introduction
11.19.4 Cytovia Revenue in Allogeneic Universal Cell Therapy Business (2019-2024)
11.19.5 Cytovia Recent Development
11.20 BeiGene
11.20.1 BeiGene Company Detail
11.20.2 BeiGene Business Overview
11.20.3 BeiGene Allogeneic Universal Cell Therapy Introduction
11.20.4 BeiGene Revenue in Allogeneic Universal Cell Therapy Business (2019-2024)
11.20.5 BeiGene Recent Development
11.21 Cell-Origin
11.21.1 Cell-Origin Company Detail
11.21.2 Cell-Origin Business Overview
11.21.3 Cell-Origin Allogeneic Universal Cell Therapy Introduction
11.21.4 Cell-Origin Revenue in Allogeneic Universal Cell Therapy Business (2019-2024)
11.21.5 Cell-Origin Recent Development
11.22 Neukio
11.22.1 Neukio Company Detail
11.22.2 Neukio Business Overview
11.22.3 Neukio Allogeneic Universal Cell Therapy Introduction
11.22.4 Neukio Revenue in Allogeneic Universal Cell Therapy Business (2019-2024)
11.22.5 Neukio Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock